• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
GCI
Click for more information
0.25% $2.05

GRYPHON CAPITAL INCOME TRUST - Corporate Spotlight

Market Cap $686.2M  ! watchlist Created with Sketch. Add to my watchlist

Gryphon Capital Income Trust (the Trust) is an Australia-based managed investment scheme.... Gryphon Capital Income Trust (the Trust) is an Australia-based managed investment scheme. The Trust’s investment objective is to produce a regular and sustainable monthly income while keeping capital preservation as a primary concern. The Trust is designed for investors who seek regular, sustainable monthly income and where capital preservation is a primary objective. The Trust invests in structured credit markets, primarily residential mortgage-backed securities (RMBS), a defensive and loss-remote asset class. The Trust is a fixed-income credit strategy and offers diversification from other more traditional sources of income like equities, with lower volatility of capital values and stable monthly distributions. The Trust's investment manager is Gryphon Capital Investments Pty Ltd.More

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile arrow Created with Sketch.
See benefits

No Corporate Spotlight currently available.

(20min delay)
Last
$2.05 		Change
0.005(0.25%) 		Mkt cap ! $686.2M
Open High Low Value Volume
$2.05 $2.05 $2.04 $1.038M 508.7K

Buyers (Bids)

No. Vol. Price($)
16 323583 $2.04
 

Sellers (Offers)

Price($) Vol. No.
$2.05 519977 16
View Market Depth
Last trade - 15.36pm 02/10/2024 (20 minute delay) ?
Last
$2.05 		  Change
0.005 ( 0.00 %)
Open High Low Volume
$2.05 $2.05 $2.04 199915
Last updated 15.59pm 02/10/2024 ?
GCI (ASX) Chart

Top Stories

Cobalt Blue sees A$60M price tag for Kwinana, WA refinery – but $68M value for stage one

Cobalt Blue has released estimates for what it would take to get its proposed Kwinana refinery off the ground, seeing CapEx of $60M.
Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger Recce Pharmaceuticals (ASX:RCE) has been on a tear this year. It's developing anti-infective, R327, with clinical results across Diabetic Foot Infection, Acute Bacterial Skin & Skin Structure Infection, and, Urosepsis/UTIs which point to a potential commercial value proposition. It also has a recent key relationship in Indonesia.
Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia Coda Minerals (ASX:COD) CEO, Chris Stevens, joins The Market Online to discuss the company's current rights issue, and how the capital from this raise will be used to further its copper exploration in South Australia. In addition, Chris talks through the journey the company has taken over the last few years since listing until now.
SPC to merge with Original Juice Co and Nature One Dairy The Original Juice Co Ltd has set up a transaction which will see it merge with Aussie icon SPC Global and Singapore-based Nature One Dairy
Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals Actinogen Medical is developing a promising oral treatment for Alzheimer's and depression and is accelerating clinical trials with new capital.
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.